Recombinant human CTLA-4-FC fusion protein for injection(Beijing Weidejie Biotechnology)

Primary objectives: 1) To evaluate the tolerability and safety of single-dose, intravenous infusion, and dose escalation of recombinant human CTLA-4-Fc fusion protein for injection (VDJ002) in healthy adult Chinese subjects. 2) To evaluate the pharmacokinetic (PK) characteristics of single-dose and intravenous infusion of recombinant human CTLA-4-Fc fusion protein for injection (VDJ002) in healthy adult Chinese subjects. Secondary objectives: 1) To evaluate the immunogenicity of single-dose recombinant human CTLA-4-Fc fusion protein for injection (VDJ002) in healthy adult Chinese subjects. 2) To preliminarily explore the pharmacodynamic (PD) characteristics of single-dose recombinant human CTLA-4-Fc fusion protein for injection (VDJ002) in healthy adult Chinese subjects.